Standard BioTools (LAB) Stock Price, News & Analysis

Company Overview

Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.

Key Stats

• Today's Range: $1.56 to $1.63
• 50-Day Range: $1.50 to $2.26
• 52-Week Range: $1.21 to $3.04
• Volume: 252,833 shs
• Average Volume: 2.46 million shs
• Market Capitalization: $593.75 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.88
• Consensus Rating: Buy

Standard BioTools Stock Analysis - MarketRank™

Standard BioTools scored higher than 64% of companies evaluated by MarketBeat, and ranked 397th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Standard BioTools has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Standard BioTools has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Standard BioTools are expected to grow in the coming year, from ($0.29) to ($0.24) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Standard BioTools is -2.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Standard BioTools is -2.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Standard BioTools has a P/B Ratio of 1.23. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.42% of the float of Standard BioTools has been sold short.

Short Interest Ratio / Days to Cover

Standard BioTools has a short interest ratio ("days to cover") of 10, which indicates bearish sentiment.

Change versus previous month

Short interest in Standard BioTools has recently decreased by 8.39%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Standard BioTools does not currently pay a dividend.

Dividend Growth

Standard BioTools does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.42% of the float of Standard BioTools has been sold short.

Short Interest Ratio / Days to Cover

Standard BioTools has a short interest ratio ("days to cover") of 10, which indicates bearish sentiment.

Change versus previous month

Short interest in Standard BioTools has recently decreased by 8.39%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: N/A

News Sentiment

Standard BioTools has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Standard BioTools this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for LAB on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

3 people have added Standard BioTools to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Standard BioTools insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,894,673.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

53.10% of the stock of Standard BioTools is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

53.74% of the stock of Standard BioTools is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

LAB Stock Analysis - Frequently Asked Questions

How have LAB shares performed this year?

Standard BioTools' stock was trading at $2.21 on January 1st, 2024. Since then, LAB stock has decreased by 27.1% and is now trading at $1.61.
View the best growth stocks for 2024 here.

Who are Standard BioTools' major shareholders?

Standard BioTools' top institutional shareholders include Sumitomo Mitsui Trust Group Inc. (2.58%), ARK Investment Management LLC (2.41%), Geode Capital Management LLC (1.87%) and Hollow Brook Wealth Management LLC (1.49%). Insiders that own company stock include Casdin Partners Master Fund, L and Caligan Partners Lp.
View institutional ownership trends.

How do I buy shares of Standard BioTools?

Shares of LAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Standard BioTools own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Standard BioTools investors own include American Water Works (AWK), The RMR Group (RMR), Waste Connections (WCN), AUO (AUOTY), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR).

Company Calendar

• Today: 11/21/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 2/26/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Analytical instruments
• Sub-Industry: Measuring And Control Equipment
• Current Symbol: NASDAQ:LAB
• CUSIP: N/A
• CIK: 1162194
• Web: www.fluidigm.com
• Phone: (650) 266-6000
• Fax: 650-871-7152
• Employees: 620
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $2.88
• High Stock Price Target: $3.25
• Low Stock Price Target: $2.50
• Potential Upside/Downside: +78.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.71)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-74,660,000.00
• Net Margins: -79.92%
• Pretax Margin: -79.83%
• Return on Equity: -27.05%
• Return on Assets: -15.52%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.76
• Quick Ratio: 3.41

Sales & Book Value

• Annual Sales: $106.34 million
• Price / Sales: 5.64
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.31 per share
• Price / Book: 1.23

Miscellaneous

• Outstanding Shares: 372,260,000
• Free Float: 174,589,000
• Market Cap: $599.34 million
• Optionable: Optionable
• Beta: 1.57